Answers are grounded in this paper and cite their sources.
Funding sources: none. Conflicts of interest: none declared. Dear Editor, Pityriasis rubra pilaris (PRP) manifests with erythematous scaly plaques, typically involving the scalp, trunk and limbs, associated with a yellowish diffuse palmoplantar keratoderma (PPK).1 Familial PRP is a very rare entity, which is inherited as an autosomal dominant trait.1 Recently, gain‐of‐function mutations in CARD14, which encodes the caspase recruitment domain family member 14, were identified as the cause of familial PRP and found to be associated with increased expression of CARD14 in the epidermis of affected patients.2 CARD14 is a known activator of the noncanonical nuclear factor‐kappa B (NF‐κB) pathway, leading to the activation of the inflammatory response.3 Herein, we describe the beneficial effect of ustekinumab in a case of familial PRP caused by a novel mutation in CARD14 that was refractory to multiple other therapeutic approaches. A 57‐year‐old man was referred for investigation of near‐erythroderma. The patient had experienced erythematous scaly plaques over most parts of the body since childhood. His father, a younger sister and his daughter were similarly affected (Fig. 1a). Physical examination revealed a diffuse and symmetric rash, involving the trunk and limbs, consisting of large scaly plaques and distinct islands of sparing. PPK and follicular accentuation were also noted (Fig. 1b,c). The patient was obese. Initially, psoriasis was diagnosed, but the clinical findings were, upon reconsideration during subsequent visits, deemed more consistent with PRP. Histopathology was not conclusive, showing epithelial hyperplasia with alternating para‐ and orthohyperkeratosis, and a mild lymphohistiocytic perivascular infiltrate (not shown).
No takes yet. Share an insight, caveat, or question.
Eytan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: